Skip to main content
All lobbying filings

TODD STRATEGY GROUP

Lobbying for AMGEN INC. · Biotechnology company.

 Filing 2nd Quarter - Report
Reporting period
2nd Quarter 2026
Apr 1 - June 30 · Posted Jul 20, 2026
Income
$80,000.00
What the client paid this registrant for the period.
Client based in
District of Columbia

Official filing document

 Lobbyists on this filing 5
  • PAUL EDATTEL
    Previously held: Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg
  • DANIEL M TODD
    Previously held: Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Amin Ctr. Medicare & Medicaid
  • ERIC BERGREN
    Previously held: Chief of Staff, Rep. Brett Guthrie; Staff Assistant, Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director, Chief of Staff - Rep. Ron Lewis; Intern, Rep. Bill Baker
  • KATHERINE FLEMING COTTON
    Previously held: Staff Assistant, Legislative Correspondent, Legislative Assistant - U.S. Representative Brett Guthrie
  • NICOLAS MAGALLANES
    Previously held: Senior Advisor - House Republican Conference; Policy Advisor/Professional Staff Member - U.S. Representative Lee Terry/Energy and Commerce Committee; Legislative Correspondent/Legislative Aide - U.S. Senator Lamar Alexander

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 3
  • Health & Human Services, Dept of (HHS)
  • HOUSE OF REPRESENTATIVES
  • SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Lobbying activity 3
Medicare/Medicaid

Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022.

Health Issues

Prescription Drug Pricing Policy. Supply Chain Issues.

Taxation/Internal Revenue Code

Prescription drug pricing policy.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem